BioCentury | May 2, 2019
Company News

AstraZeneca adds oncolytic virus option through Transgene deal

...Growth" ). The Transgene deal is AZ's second agreement involving an oncolytic virus. In 2015, Omnis Pharma Inc....
BioCentury | Mar 21, 2016
Company News

Magnis Therapeutics, Omnis Pharma deal

...and Imanis. The companies declined to disclose financial terms. Magnis Therapeutics LLC , Rochester, Minn. Omnis Pharma Inc....
BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

...of those cocktails, or engage in R&D collaborations with biotechs developing viruses. In January 2015 Omnis Pharma Inc....
...Mayo Clinic, Rochester, Minn. MedImmune LLC, Gaithersburg, Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Omnis Pharma Inc....
Items per page:
1 - 3 of 3
BioCentury | May 2, 2019
Company News

AstraZeneca adds oncolytic virus option through Transgene deal

...Growth" ). The Transgene deal is AZ's second agreement involving an oncolytic virus. In 2015, Omnis Pharma Inc....
BioCentury | Mar 21, 2016
Company News

Magnis Therapeutics, Omnis Pharma deal

...and Imanis. The companies declined to disclose financial terms. Magnis Therapeutics LLC , Rochester, Minn. Omnis Pharma Inc....
BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

...of those cocktails, or engage in R&D collaborations with biotechs developing viruses. In January 2015 Omnis Pharma Inc....
...Mayo Clinic, Rochester, Minn. MedImmune LLC, Gaithersburg, Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Omnis Pharma Inc....
Items per page:
1 - 3 of 3